Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AKRO
stocks logo

AKRO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.986
-0.4%
--
--
-1.010
+12.22%
--
--
-1.033
+20.15%
Estimates Revision
Stock Price
Go Up
up Image
+22.16%
In Past 3 Month
Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is 60.22 USD with a low forecast of 54.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is 60.22 USD with a low forecast of 54.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 54.630
sliders
Low
54.00
Averages
60.22
High
84.00
Current: 54.630
sliders
Low
54.00
Averages
60.22
High
84.00
H.C. Wainwright
Andrew Fein
initiated
$72
2025-09-04
Reason
H.C. Wainwright
Andrew Fein
Price Target
$72
2025-09-04
initiated
Reason
H.C. Wainwright analyst Andrew Fein assumed coverage of Akero Therapeutics with a Buy rating and $72 price target. Th firm says efruxifermin's cirrhosis reversal and Phase 3 readouts support a bullish share view.
TD Cowen
NULL -> Buy
initiated
$76
2025-08-04
Reason
TD Cowen
Price Target
$76
2025-08-04
initiated
NULL -> Buy
Reason
TD Cowen initiated coverage of Akero Therapeutics with a Buy rating and $76 price target. The firm believes the company's efruxifermin, an FGF21 analog, has a "differentiated" clinical profile and see commercial success in metabolic dysfunction-associated steatohepatitis. Efruxifermin, is in Phase 3 trials with high probabilities of success, the analyst tells investors in a research note.
BofA
Buy
maintain
$63 -> $64
2025-05-27
Reason
BofA
Price Target
$63 -> $64
2025-05-27
maintain
Buy
Reason
Citi
Buy
downgrade
$80 -> $78
2025-05-13
Reason
Citi
Price Target
$80 -> $78
2025-05-13
downgrade
Buy
Reason
Citi lowered the firm's price target on Akero Therapeutics to $78 from $80 and keeps a Buy rating on the shares. The company reported Q1 earnings after it revealed clinical data from its Phase 2b SYMMETRY trial at the European Association for the Study of the Liver conference last week, the analyst tells investors in a research note. The firm says the detailed data showed that efruxifermin treatment led to improvements on multiple noninvasive measures of liver fibrosis, adding on to 96-week topline liver biopsy data released earlier this year.
Morgan Stanley
Overweight
downgrade
$90 -> $84
2025-05-12
Reason
Morgan Stanley
Price Target
$90 -> $84
2025-05-12
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Akero Therapeutics to $84 from $90 and keeps an Overweight rating on the shares. Q1 results were uneventful, following multiple data updates last week, further confirming robust benefits on fibrosis, while execution across the Phase 3 SYNCHRONY program continues to be on track, the analyst tells investors in a research note. The firm updated its model to reflect the report and recent trends, specifically reducing its initial EFX sales and increasing its outer year sales tot reflect a more conservative view on the timing of a U.S. launch in F5 patients, pending outcomes data.
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$72 → $75
2025-03-03
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$72 → $75
2025-03-03
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Akero Therapeutics Inc (AKRO.O) is -13.35, compared to its 5-year average forward P/E of -9.02. For a more detailed relative valuation and DCF analysis to assess Akero Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.02
Current PE
-13.35
Overvalued PE
-5.08
Undervalued PE
-12.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.29
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.55
Undervalued EV/EBITDA
-10.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 117.24% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AKRO News & Events

Events Timeline

(ET)
2025-11-07
07:07:39
Akero Therapeutics Reveals New Results from SYMMETRY and HARMONY Trials
select
2025-10-09 (ET)
2025-10-09
12:00:41
Akero Therapeutics Sees 16.6% Increase
select
2025-10-09
10:00:04
Akero Therapeutics Sees 16.5% Increase
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-20Globenewswire
Halper Sadeh LLC Urges Shareholders of SEE, AXTA, SEMR, and AKRO to Reach Out for Rights Consultation

  • Investigation of Companies: Halper Sadeh LLC is investigating Sealed Air Corporation, Axalta Coating Systems, Semrush Holdings, and Akero Therapeutics for potential violations of federal securities laws and breaches of fiduciary duties related to their sales to other companies.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to learn about their rights and options regarding the proposed transactions, with Halper Sadeh LLC offering legal assistance on a contingent fee basis.

  • Legal Support Offered: The law firm represents investors globally who have experienced securities fraud and corporate misconduct, aiming to seek increased consideration and additional disclosures for shareholders.

  • Contact Information: Interested shareholders can contact Halper Sadeh LLC for a free consultation regarding their legal rights, with provided contact details for attorneys Daniel Sadeh and Zachary Halper.

[object Object]
Preview
7.0
11-18PRnewswire
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights

  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales and mergers of several companies, including WideOpenWest, Akero Therapeutics, Heritage Financial, and Berry Corporation.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, as the firm may seek increased consideration or additional disclosures on their behalf.

  • Contingent Fee Basis: The firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover losses and implement corporate reforms.

[object Object]
Preview
7.0
11-12PRnewswire
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

  • Investigation of Companies: Halper Sadeh LLC is investigating Nicolet Bankshares, Akero Therapeutics, and Barinthus Biotherapeutics for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their respective mergers and sales.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their rights and options, as the firm may seek increased consideration or additional disclosures on their behalf.

  • Contingent Fee Basis: The legal actions will be handled on a contingent fee basis, meaning shareholders will not incur out-of-pocket expenses for legal fees or costs.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to implement corporate reforms and recover funds for affected investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Akero Therapeutics Inc (AKRO) stock price today?

The current price of AKRO is 54.63 USD — it has decreased -0.11 % in the last trading day.

arrow icon

What is Akero Therapeutics Inc (AKRO)'s business?

Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

arrow icon

What is the price predicton of AKRO Stock?

Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is 60.22 USD with a low forecast of 54.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Akero Therapeutics Inc (AKRO)'s revenue for the last quarter?

Akero Therapeutics Inc revenue for the last quarter amounts to -90.24M USD, increased 10.44 % YoY.

arrow icon

What is Akero Therapeutics Inc (AKRO)'s earnings per share (EPS) for the last quarter?

Akero Therapeutics Inc. EPS for the last quarter amounts to -67171000.00 USD, decreased -4.62 % YoY.

arrow icon

What changes have occurred in the market's expectations for Akero Therapeutics Inc (AKRO)'s fundamentals?

The market is revising No Change the revenue expectations for AKRO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 22.16%.
arrow icon

How many employees does Akero Therapeutics Inc (AKRO). have?

Akero Therapeutics Inc (AKRO) has 63 emplpoyees as of December 05 2025.

arrow icon

What is Akero Therapeutics Inc (AKRO) market cap?

Today AKRO has the market capitalization of 4.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free